Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 163   

Articles published

NVS 79.52 -1.70 (-2.09%)
price chart
Novartis AG (ADR) 17% Potential Upside Now Implied by Chardan Capital Markets
Novartis AG (ADR) with TICKER NYSE:NVS has had its stock rating noted as 'Initiated' with the recommendation being set at 'BUY' yesterday by analysts at Chardan Capital Markets.
Novartis Ag (NYSE:NVS) Is A Stock Chardan Capital Is Interested In  Post News
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen?  Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy  Bidness ETC
How Many Heart Failure Deaths Can Novartis AG (ADR) (NYSE:NVS) Entresto Reduce?
A fresh analysis of Novartis AG (ADR) (NYSE:NVS) drug Entresto has shown that it can significantly reduce heart failure deaths.
Xencor Inc (NASDAQ:XNCR) to Collaborate with Pharma Giant Novartis AG (ADR ...
Xencor Inc (NASDAQ:XNCR) shares rose 32.06% to $16.56 on Tuesday after the company officially signed its collaboration agreement with Novartis AG (ADR) (NYSE:NVS), which has agreed to pay $150 million to have access to Xencor's top two product ...
Novartis AG (NYSE:NVS) Betting On Xencor's Two Drug Candidates With $2.4 ...  Market Exclusive
Xencor Stock Up On Cancer Drugs Partnership with Novartis  Zacks.com
Novartis AG (ADR) (NVS) Under Investigation for 'Sham' Events
Novartis AG (ADR) ( NVS ) is under investigation for alleged sham events it held for doctors. Novartis, NVS The U.S is seeking information regarding what it claims were 80,000 sham events .
Citi Downgrades Novartis Following SAG Investigation  Benzinga
How Analysts Feel About Novartis AG (ADR) After Today's Gap Down?
The stock of Novartis AG (ADR) (NYSE:NVS) gapped down by $0.12 today and has $73.39 target or 9.00% below today's $80.65 share price.
Regulatory Filing: Bryn Mawr Trust Company Trimmed Its Novartis Ag Sponsored ...
Bryn Mawr Trust Company decreased its stake in Novartis Ag Sponsored Adr (NVS) by 68.65% based on its latest 2016Q2 regulatory filing with the SEC.
Novartis Sees Lower Rate Of Disease Progression In MS Patients Using Gilenya ...  Press Telegraph
Hedge Funds Aren't Crazy About Novartis AG (ADR) (NVS) Anymore
We can judge whether Novartis AG (ADR) (NYSE:NVS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
Novartis AG (ADR) Aiming to Target Biosimilar Market by 2020
By 2020, Novartis AG (NYSE:NVS) plans to launch a number of biosimilar versions of the blockbuster drugs in order to enter multiple therapeutic markets.